Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to ...

Caribou Biosciences announces new clinical trials and leadership appointments, highlighting progress in CAR-T therapy for various cancers and lupus. Caribou Biosciences, Inc. announced the initiation ...

Dosing initiated for SION-451 combined with SION-2222 and SION-451 combined with SION-109 in healthy volunteers; topline data anticipated in mid-2026 WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ...

Please provide your email address to receive an email when new articles are posted on . One in six participants in phase 2 cancer trials received a therapy that gained FDA approval. The results ...

WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, a clinical-stage biopharmaceutical company utilizing its proprietary ReSOLVE™ platform to discover and develop differentiated ...

First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD ...

ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitor NLRP3 inhibitors are a major new class of compounds linked to a broad spectrum of inflammatory conditions ...

LITTLETON, Colo., Dec. 12, 2024 /PRNewswire/ -- DeFloria, a joint venture between Ajna BioSciences and Charlotte's Web (TSX: CWEB, OTCQX: CWBHF), reported positive results from a Phase 1 single ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Prior to this trial, CS014 had positive outcomes in an ...

Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 WATERTOWN, Mass., Feb. 23, 2026 ...